Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paroxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | GRK2 | P25098 | 4/20 | 0.98 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | TP53 | P04637 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.98 |
| ▸ | THPO | P40225 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | NPC1 | O15118 | 1/20 | 0.98 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paroxetine SCHEMBL18937018 | 1.00 | CYP3A4 (0.98) | CYP3A4GRK2MEN1KMT2ASLC6A4 | |
| Paroxetine SCHEMBL145268 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ASLC6A4 | |
| Paroxetine SCHEMBL27521044 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ASLC6A4 | |
| Paroxetine SCHEMBL7247758 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ASLC6A4 | |
| Paroxetine SCHEMBL145267 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ASLC6A4 | |
| Paroxetine SCHEMBL10643985 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ASLC6A4 | |
| Paroxetine SCHEMBL1286957 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ASLC6A4 | |
| Paroxetine SCHEMBL1945816 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ASLC6A4 | |
| Paroxetine SCHEMBL15855060 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ASLC6A4 | |
| Paroxetine SCHEMBL8732632 | 0.99 | CYP3A4 (1.00) | CYP3A4GRK2MEN1KMT2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168584-B1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMBINATION OF A TRIAZOLOBENZODIAZEPINE AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR | PPTM INTERNAT S R L (LU) | 2014-08-20 | — | — | EP | claimed |
| EP-2168584-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMBINATION OF A TRIAZOLOBENZODIAZEPINE AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR | World Trade Import-Export, WTIE A.G. (CH) | 2010-03-31 | — | — | EP | claimed |
| EP-1726591-B1 | Process for manufacturing paroxetine hydrochloride hemihydrate | APOTECNIA S A (ES) | 2008-09-10 | — | — | EP | claimed |
| EP-0923554-B1 | N-BENZYLPIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | RICHTER GEDEON VEGYESZET (HU) | 2002-01-09 | — | — | EP | claimed |
| CN-116018131-A | Fast orodispersible tablet with inner cavity | 阿普雷奇亚制药有限责任公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-2168584-B1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMBINATION OF A TRIAZOLOBENZODIAZEPINE AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR | PPTM INTERNAT S R L (LU) | 2014-08-20 | — | — | EP | disclosed |
| EP-2168584-A1 | PHARMACEUTICAL COMPOSITION COMPRISING THE COMBINATION OF A TRIAZOLOBENZODIAZEPINE AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR | World Trade Import-Export, WTIE A.G. (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20090326233-A1 | 4-PHENYLPIPERIDINE COMPOUNDS | JDS NEURO, LLC | 2009-12-31 | — | — | US | disclosed |
| US-7598271-B1 | Crystalline paroxetine methane sulfonate | NOVEN THERAPEUTICS, LLC (US) | 2009-10-06 | — | — | US | disclosed |
| US-20050277669-A1 | Preparation of paroxetine involving novel intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2005-12-15 | — | — | US | disclosed |
| US-6956121-B2 | Preparation of paroxetine involving novel intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-10-18 | — | — | US | disclosed |
| EP-1482939-A4 | PREPARATION OF PAROXETINE INVOLVING NOVEL INTERMEDIATES | TEVA PHARMA (IL) | 2005-10-12 | — | — | EP | disclosed |
| WO-2000078753-A1 | PROCESS FOR THE PREPARATION OF PAROXETINE AND STRUCTURALLY RELATED COMPOUNDS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000039090-A1 | PROCESS FOR THE PREPARATION OF PAROXETINE ACETATE AND ANALOGUES THEREOF | SMITHKLINE BEECHAM PLC (GB) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000039121-A1 | PROCESS FOR THE PREPARATION OF AN ACETATE SALT OF PAROXETINE OR PAROXETINE ANALOGUES | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000039122-A1 | PROCESS FOR THE PREPARATION OF AN ACETATE SALT OF PAROXETINE OR PAROXETINE ANALOGUES | SMITHKLINE BEECHAM PLC (GB) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000039123-A1 | PROCESS FOR THE PREPARATION OF AN ACETATE SALT OF PAROXETINE OR PAROXETINE ANALOGUES | SMITHKLINE BEECHAM PLC (GB) | 2000-07-06 | — | — | WO | disclosed |
| EP-0994872-A1 | 4-PHENYLPIPERIDINE COMPOUNDS | Synthon B.V. (NL) | 2000-04-26 | — | — | EP | disclosed |
| US-5874447-A | HIGH PURITY ORGANOSULFONATE SALT OF PAROXETINE WITH EXCELLENT STABILITY, SOLUBILITY; REACT WITH A BASE TO MAKE HIGH PURITY PAROXETINE, OR WITH A REAGENT TO MAKE THE HIGH PURITY SALT OF SAID REAGENT (EX: PAROXETINE MALEATE FROM MALEIC ACID) | SYNTHON B. V. (NL) | 1999-02-23 | — | — | US | disclosed |
| WO-1998056787-A1 | 4-Phenylpiperidine compounds | SYNTHON B.V. (NL) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326233-A1 | 4-PHENYLPIPERIDINE COMPOUNDS | ABCC4, DRD4, PAH | SLC6A4 151/4885CYP3A4 12/4885GRK2 290/4885 |
| US-20050277669-A1 | Preparation of paroxetine involving novel intermediates | HTR6, HTR5A, CYP2B6 | SLC6A4 5/4885CYP3A4 17/4885GRK2 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.